SCHEMBL4235491

SCHEMBL4235491

CCCCN1CCC(Oc2ccc(C(=O)Nc3ccc(Oc4ccc(NC(=O)NC(C)C)cc4)cc3)cc2)CC1

nearest known ligand 0.48

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HRH3 Q9Y5N1 8/20 0.48
MAPT P10636 3/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
TAAR1 Q96RJ0 1/20 0.44
HSD17B10 Q99714 1/20 0.44
LMNA P02545 2/20 0.44
KDM4E B2RXH2 2/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
MCHR2 Q969V1 1/20 0.43
MCHR1 Q99705 1/20 0.43
MMP2 P08253 1/20 0.43
NAMPT P43490 2/20 0.42
OPRM1 P35372 2/20 0.42
OPRD1 P41143 2/20 0.42
ALDH1A1 P00352 2/20 0.42
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4236380 0.93 HRH3 (0.47) HRH3MAPTHPGDTSHRTAAR1
SCHEMBL4238075 0.93 HRH3 (0.44) HRH3MAPTHPGDTSHRTAAR1
SCHEMBL4229358 0.92 HRH3 (0.47) HRH3MAPTHPGDTSHRTAAR1
SCHEMBL4231991 0.92 PKM (0.45) HRH3MAPTHPGDTSHRTAAR1
SCHEMBL4236986 0.90 MCHR1 (0.43) HRH3SMN1; SMN2MCHR2MCHR1NAMPT
SCHEMBL4235464 0.90 MCHR1 (0.44) HRH3TSHRMCHR2MCHR1NAMPT
SCHEMBL4233415 0.90 MCHR1 (0.50) HRH3MAPTSMN1; SMN2MCHR2MCHR1
SCHEMBL4231873 0.90 CHRM3 (0.43) HRH3LMNASMN1; SMN2MCHR1NAMPT
SCHEMBL4233635 0.90 HRH3 (0.42) HRH3MAPTHPGDTSHRTAAR1
SCHEMBL4232252 0.88 HRH3 (0.42) HRH3LMNAMCHR1NAMPTOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US claimed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed
US-20090233910-A1 Npy antagonists, preparation and uses CEREP (FR) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233910-A1 Npy antagonists, preparation and uses NPY1R, NPY5R, NPY2R HRH3 210/4885MAPT 1398/4885HPGD 1474/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.